Our People

Ron Renaud

Ron Renaud
EXPERIENCE

Mr. Renaud joined Bain Capital in 2022. He is Partner on the Bain Capital Life Sciences team. From 2014 to 2021, he was Chief Executive Officer of Translate Bio (Nasdaq: TBIO) which was acquired by Sanofi in 2021. Prior to that he was President and Chief Executive Officer of Idenix Pharmaceuticals (Nasdaq: IDIX) which was acquired by Merck in 2014. Prior to his career in the biotech industry, Ron was a biotechnology research analyst at JP Morgan and Bear Stearns. Earlier in his career, Ron held various roles at Amgen (Nasdaq: AMGN) as well as at the Dana-Farber Cancer Institute.

EDUCATION

Mr. Renaud received an MBA from the University of Southern California Marshall School of Business and a BA from Saint Anselm College.